JP2009523459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523459A5 JP2009523459A5 JP2008551863A JP2008551863A JP2009523459A5 JP 2009523459 A5 JP2009523459 A5 JP 2009523459A5 JP 2008551863 A JP2008551863 A JP 2008551863A JP 2008551863 A JP2008551863 A JP 2008551863A JP 2009523459 A5 JP2009523459 A5 JP 2009523459A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- recombinant fusion
- variable domain
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 65
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 13
- 108060003951 Immunoglobulin Proteins 0.000 claims 12
- 102000018358 immunoglobulin Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 7
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 3
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 3
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 2
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims 2
- 102000000479 TCF Transcription Factors Human genes 0.000 claims 2
- 108010016283 TCF Transcription Factors Proteins 0.000 claims 2
- 102000019997 adhesion receptor Human genes 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002439 hemostatic effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 claims 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 claims 1
- XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 108010036320 valylleucine Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76170806P | 2006-01-24 | 2006-01-24 | |
| PCT/GB2006/004559 WO2007066106A1 (en) | 2005-12-06 | 2006-12-05 | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| PCT/GB2007/000227 WO2007085814A1 (en) | 2006-01-24 | 2007-01-24 | Fusion proteins that contain natural junctions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523459A JP2009523459A (ja) | 2009-06-25 |
| JP2009523459A5 true JP2009523459A5 (enExample) | 2010-03-11 |
Family
ID=38028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20110159003A1 (enExample) |
| EP (1) | EP1976882A2 (enExample) |
| JP (2) | JP2009523460A (enExample) |
| KR (1) | KR20080098382A (enExample) |
| CN (1) | CN101578298A (enExample) |
| AU (1) | AU2007209202A1 (enExample) |
| BR (1) | BRPI0710572A2 (enExample) |
| CA (1) | CA2636854A1 (enExample) |
| CR (1) | CR10179A (enExample) |
| EA (1) | EA200801515A1 (enExample) |
| IL (1) | IL192572A0 (enExample) |
| MA (1) | MA30175B1 (enExample) |
| NO (1) | NO20082942L (enExample) |
| TW (2) | TW200804593A (enExample) |
| WO (1) | WO2007085815A2 (enExample) |
| ZA (1) | ZA200806202B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| WO2009138413A1 (en) * | 2008-05-15 | 2009-11-19 | Domantis Limited | Single domain antibodies that bind il-13 |
| WO2007134050A2 (en) * | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2009030285A1 (en) * | 2007-09-07 | 2009-03-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2036980A1 (de) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| AU2017201007B2 (en) * | 2007-10-15 | 2018-12-13 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
| CA2707986A1 (en) * | 2007-12-13 | 2009-06-18 | Glaxo Group Limited | Compositions for pulmonary delivery |
| EP2238165B1 (en) * | 2008-01-07 | 2017-07-05 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-hiv domain antibodies and method of making and using same |
| RU2607569C2 (ru) * | 2008-03-31 | 2017-01-10 | Дженентек, Инк. | Композиции и способы для лечения и диагностики астмы |
| WO2009127691A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| AU2009306424A1 (en) * | 2008-10-21 | 2010-04-29 | Domantis Limited | Ligands that have binding specificity for DC-SIGN |
| CN102307896B (zh) | 2008-10-31 | 2016-10-12 | 森托科尔奥索生物科技公司 | 基于iii型纤连蛋白结构域的支架组合物、方法及用途 |
| EP2358754A1 (en) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Ligands that bind il-13 |
| CN102307902B (zh) | 2008-12-10 | 2016-02-24 | 埃博灵克斯股份有限公司 | 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽 |
| EP2435482B1 (en) * | 2009-05-28 | 2019-04-03 | Glaxo Group Limited | Antigen-binding proteins |
| EA201190275A1 (ru) * | 2009-05-28 | 2012-11-30 | Глаксо Груп Лимитед | Белок, связывающий интерлейкин-13 (il-13) |
| BR112012001681A2 (pt) * | 2009-07-16 | 2019-09-24 | Graxo Group Ltd | domínios variáveis de ligação de anti-albumina sérica aperfeiçoados |
| AU2010277629B2 (en) | 2009-07-29 | 2016-05-19 | Glaxo Group Limited | Anti - TGF - beta receptor type II single domain antibodies |
| WO2011095545A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx Nv | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| HRP20191071T1 (hr) | 2010-02-11 | 2019-09-20 | Ablynx N.V. | Postupci i pripravci za pripremu aerosola |
| HUE029622T2 (en) | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| MX2013007936A (es) | 2011-01-06 | 2013-08-09 | Glaxo Group Ltd | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta. |
| EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| EP2761066B1 (en) | 2011-09-27 | 2018-12-05 | Janssen Biotech, Inc. | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
| US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| CA2876904C (en) * | 2012-06-22 | 2019-12-03 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| HUE064945T2 (hu) | 2012-08-21 | 2024-04-28 | Sanofi Biotechnology | Eljárások asztma kezelésére vagy megelõzésére IL-4R antagonista beadásával |
| WO2014030780A1 (en) * | 2012-08-22 | 2014-02-27 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
| US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
| CA2934004C (en) * | 2013-12-17 | 2023-07-04 | The Metrohealth System | Compositions and methods for treating fatty tissue buildup |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| CN106536754B (zh) | 2014-04-11 | 2021-04-16 | 诺华股份有限公司 | 用il-13拮抗剂选择性治疗哮喘的方法 |
| SI3204095T1 (sl) | 2014-10-10 | 2019-08-30 | Ablynx N.V. | Inhalacijska naprava za uporabo pri zdravljenju bolezni dihal z aerosolom |
| RU2017115670A (ru) | 2014-10-10 | 2018-11-15 | Аблинкс Н.В. | Лечение инфекции рсв |
| EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| JP6862343B2 (ja) | 2014-12-19 | 2021-04-21 | アブリンクス エン．ヴェー． | システイン結合ナノボディダイマー |
| WO2017191108A1 (en) | 2016-05-02 | 2017-11-09 | Ablynx Nv | Treatment of rsv infection |
| JP6293829B2 (ja) * | 2016-08-05 | 2018-03-14 | モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| JP7104703B2 (ja) | 2016-12-14 | 2022-07-21 | ヤンセン バイオテツク，インコーポレーテツド | Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| HUE064655T2 (hu) | 2017-10-30 | 2024-04-28 | Sanofi Biotechnology | IL-4R antagonista asztma kezelésére vagy megelõzésére szolgáló eljárásban |
| CN108855003B (zh) * | 2018-06-28 | 2021-01-05 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
| CN111518211B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
| JP2022541697A (ja) | 2019-02-27 | 2022-09-27 | ジャージャン ナノマブ テクノロジー センター カンパニー リミテッド | 高解像度で広範なエピトープを網羅するために、ラクダ科動物抗体を生成する配列ベースのハイスループット法 |
| MX2022000649A (es) | 2019-07-16 | 2022-06-08 | Sanofi Biotechnology | Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r. |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | FIBRONECTIN TYPE III DOMAINS BINDING TO CD137 |
| US20230279115A1 (en) | 2020-04-22 | 2023-09-07 | Mabwell (shanghai) Bioscience Co., Ltd. | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof |
| EP4146704A4 (en) * | 2020-05-06 | 2024-08-28 | Dragonfly Therapeutics, Inc. | ANTIBODIES DIRECTED AGAINST CLEC12A AND USE THEREOF |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| BR112023021318A2 (pt) | 2021-04-14 | 2023-12-19 | Aro Biotherapeutics Company | Conjugados de domínio fn3-sirna e usos dos mesmos |
| CA3254037A1 (en) * | 2022-03-03 | 2023-09-07 | Pfizer | MULTISPECIFIC ANTIBODIES AND THEIR USES |
| WO2024038112A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| JP2025036273A (ja) * | 2023-08-30 | 2025-03-14 | ファイザー・インク | 多重特異性抗体およびその使用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| ZA931148B (en) * | 1992-02-19 | 1993-08-18 | Schering Corp | Cloning and expression of humanized monoclonal antibodies against human interfluekin-4. |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| DK1517921T3 (da) * | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| PL1711528T3 (pl) * | 2003-12-23 | 2012-11-30 | Genentech Inc | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
| CA2554596A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 specific polypetides and therapeutic uses thereof |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006023460A2 (en) * | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
-
2007
- 2007-01-24 AU AU2007209202A patent/AU2007209202A1/en not_active Abandoned
- 2007-01-24 JP JP2008551864A patent/JP2009523460A/ja active Pending
- 2007-01-24 WO PCT/GB2007/000228 patent/WO2007085815A2/en not_active Ceased
- 2007-01-24 EA EA200801515A patent/EA200801515A1/ru unknown
- 2007-01-24 US US12/223,005 patent/US20110159003A1/en not_active Abandoned
- 2007-01-24 BR BRPI0710572-0A patent/BRPI0710572A2/pt not_active IP Right Cessation
- 2007-01-24 JP JP2008551863A patent/JP2009523459A/ja active Pending
- 2007-01-24 CN CNA2007800097556A patent/CN101578298A/zh active Pending
- 2007-01-24 TW TW096102778A patent/TW200804593A/zh unknown
- 2007-01-24 CA CA002636854A patent/CA2636854A1/en not_active Abandoned
- 2007-01-24 KR KR1020087020811A patent/KR20080098382A/ko not_active Ceased
- 2007-01-24 EP EP07705003A patent/EP1976882A2/en not_active Withdrawn
- 2007-01-24 TW TW096102774A patent/TW200740843A/zh unknown
-
2008
- 2008-05-15 US US12/152,903 patent/US20090060916A1/en not_active Abandoned
- 2008-07-02 IL IL192572A patent/IL192572A0/en unknown
- 2008-07-02 NO NO20082942A patent/NO20082942L/no not_active Application Discontinuation
- 2008-07-16 ZA ZA200806202A patent/ZA200806202B/xx unknown
- 2008-07-24 CR CR10179A patent/CR10179A/es unknown
- 2008-07-25 MA MA31143A patent/MA30175B1/fr unknown
-
2009
- 2009-05-13 US US12/992,718 patent/US20120093830A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523459A5 (enExample) | ||
| US20240124584A1 (en) | Igm fc and j-chain mutations that affect igm serum half-life | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| TWI588156B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| JP2022185021A (ja) | 多価多重特異性ｏｘ４０結合融合タンパク質 | |
| JP2022512649A (ja) | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 | |
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| BR112021006783A2 (pt) | proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer. | |
| JP2021121642A (ja) | 二特異性抗体基幹 | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2019502656A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| JP2010532764A5 (enExample) | ||
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| IL194145A (en) | Transgenic protein heterodimeric regions | |
| JPWO2019129221A5 (enExample) | ||
| KR20220093363A (ko) | N-말단 scFv 다중특이적 결합 분자 | |
| WO2001079494A1 (fr) | Anticorps agonistes | |
| Park et al. | Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens | |
| US20250197481A1 (en) | Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV | |
| TW202225188A (zh) | 與ｃｄ３結合的多肽構建體 | |
| US20250188166A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| JPWO2022150788A5 (enExample) |